Anlon Healthcare Limited has filed its annual report for the financial year ended March 31, 2026, reporting significant growth in both revenue and profitability. The company recorded a standalone revenue from operations of ₹1,764.99 crore, an increase from ₹1,202.87 crore in FY25. Standalone profit after tax (PAT) rose to ₹278.08 crore compared to ₹205.18 crore in the prior year.

The consolidated results show a revenue from operations of ₹1,719.66 crore and a consolidated PAT of ₹290.88 crore. The improvement in profitability was supported by operational efficiencies and strategic initiatives undertaken during the year.

Financial Performance

The company’s financials reflect strong top-line growth alongside improved bottom-line performance. Key figures for FY26 are outlined below:

Proposed Acquisitions

A key focus of the upcoming Annual General Meeting (AGM) is the proposed acquisition of two entities: Apiqo Organics Private Limited (AOPL) and Bizotic Lifescience Private Limited (BLPL). The company plans to acquire a 44.94% stake in AOPL and a 47.41% stake in BLPL through a share swap mechanism.

To facilitate this, Anlon Healthcare proposes a preferential allotment of up to 8,58,83,617 equity shares at a price of ₹17.85 per share. This transaction is structured as consideration other than cash, involving the issuance of swap shares to the existing shareholders of AOPL and BLPL.

• Apiqo Organics Acquisition: The company will issue approximately 6.53 crore shares to acquire the 44.94% stake in AOPL for a total consideration of ₹116.52 crore.
• Bizotic Lifescience Acquisition: Approximately 2.06 crore shares will be issued to acquire the 47.41% stake in BLPL for a total consideration of ₹36.78 crore.

Upon completion, both entities are expected to become wholly-owned subsidiaries of Anlon Healthcare, subject to regulatory approvals and the transfer of remaining shares from minority shareholders.

Capital Structure Changes

The company also seeks approval to enhance its authorized share capital from ₹110 crore to ₹130 crore. This involves the creation of additional 10 crore equity shares of ₹2 each. This move supports the company’s long-term growth strategy and provides flexibility for future capital requirements.

Corporate Governance and AGM

The 13th Annual General Meeting is scheduled for September 5, 2026. Other agenda items include the reappointment of Chairman and Managing Director Punitkumar Rasadia and the appointment of Kishan Vinodkumar Raja as an Independent Director.

The company successfully completed its Initial Public Offering (IPO) in August 2025, raising ₹121.03 crore. It also executed a 1:1 bonus issue and a 1:5 stock split during the year, reflecting confidence in its long-term value creation.

What the Numbers Show

The divergence between standalone and consolidated revenues—₹1,764.99 crore versus ₹1,719.66 crore respectively—highlights the impact of recent acquisitions on the group structure. While standalone operations drove the primary growth engine, the consolidated figures include subsidiaries acquired later in the fiscal year (AOPL in January 2026 and BLPL in March 2026), indicating that full-year integration benefits will likely be more visible in subsequent periods.

Anlon Healthcare is seeking shareholder approval at its upcoming Annual General Meeting to acquire controlling stakes in two pharmaceutical entities through a significant share swap transaction. The company aims to acquire a 44.94% shareholding in Apiqo Organics Private Limited (AOPL) and a 47.41% shareholding in Bizotic Lifescience Private Limited (BLPL), which will result in both becoming wholly owned subsidiaries upon completion.

The acquisition involves the preferential allotment of up to 8,58,83,617 fully paid-up equity shares of face value ₹2 each. These shares will be issued at a price of ₹17.85 per share, including a security premium of ₹15.85. The total consideration for the AOPL acquisition is valued at ₹1,165,179,600, while the BLPL acquisition carries a total purchase consideration of ₹367,840,000.

Transaction Structure

The swap ratio and share allotment details are structured as follows:

The floor price for the issue was determined as ₹17.78 per equity share, based on the volume-weighted average price on the National Stock Exchange during the 90 trading days preceding August 6, 2026. An independent valuer, CA Gaurang Agarwal, confirmed this fair value in a report dated August 6, 2026.

Strategic Rationale

The company stated that full ownership of AOPL and BLPL will provide greater flexibility in implementing business strategies, allocating resources, and undertaking future expansion initiatives. The move is expected to strengthen Anlon Healthcare’s position in the healthcare and pharmaceutical sector by consolidating financial performance and operations. The transactions are classified as material related-party transactions under SEBI Listing Regulations, requiring prior shareholder approval.

Other Agenda Items

The AGM, scheduled for September 5, 2026, at 11:00 am via video conference, includes several other resolutions:

• Director Appointments: Reappointment of Punitkumar Rameshbhai Rasadia, who retires by rotation, and appointment of Kishan Vinodkumar Raja as an Independent Director.
• Capital Increase: Enhancement of authorized share capital from ₹110 crore to ₹130 crore by creating 10 crore additional equity shares.
• Related Party Transactions: Approval for future transactions with AOPL up to ₹80 crore and with BLPL up to ₹60 crore during FY27, primarily for the sale and purchase of goods.
• Cost Auditor: Ratification of remuneration for M/s M. C. Bambhroliya & Associates as Cost Auditor for FY27.

What the Numbers Show

The proposed share swap represents a substantial consolidation strategy without immediate cash outflow. By issuing new equity worth ₹1,533 crore (combined consideration) to existing shareholders of the target entities, Anlon Healthcare is leveraging its listed status to absorb unlisted or partially held assets. The issuance price of ₹17.85 is marginally higher than the regulatory floor price of ₹17.78, indicating minimal premium over the mandated minimum, which suggests a negotiated settlement focused on compliance rather than market premium capture for the selling shareholders.